Chronimed
This article was originally published in The Tan Sheet
Executive Summary
Signs exclusive worldwide license with Harvard to market the vitamin A palmitate used in the Berson, et al. study (see above), a form and dosage of vitamin A not previously available. The product, called Unilife-A, will be marketed by Minneapolis-based Chronimed's Orphan Medical division.